http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
서숙원 ( Suk Won Seo ),김천희 ( Chun Hee Kim ),지현숙 ( Hyun Sook Chi ) 대한임상검사과학회 2004 대한임상검사과학회지(KJCLS) Vol.36 No.1
Bone marrow transplantation(BMT) is widely used as curative means of various malignant and nonmalignant hematologic disorders, and early and accurate determination of engraftment is very important for critical management decisions. Reticulocyte counts performed by automated flow cytometric methods is a good indicator of erythropoietic activity and its evaluation has been proposed as an early predictor of bone marrow regeneration. Some reports highlighted the usefulness of the percentage of highly fluorescent reticulocytes and the sum of highly and medium fluorescent reticulocytes(immature reticulocyte fraction, IRF). In Asan Medical Center, the criteria for engraftment following BMT or PBSCT was defined as the first day of a 3-day trend of absolute neutrophil count(ANC)≥ 500/uL and platelet count≥ 30× 103/uL. In 1999, Grotto et al proposed an indidator of bone marrow recovery as the first day on which the IRF was twice the minimum value after bone marrow transplantation. To compare the both criterias, we got consecutive datas of immature reticulocyte fraction, absolute neutrophil count(ANC), WBC count, platelet count and reticulocyte count by XE-2100 automated hematology analyzer(Sysmex Co. Japan) from 33 patients daily after BMT. When compared to standard neutrophil engraftment(10-30 days, 16.2 ± 4.6 days), IRF engraftment (5-21 days, 11.0 ± 3.9 days) occured significantly earlier in 87.9% of patients(P<0.05). The mean engraftment day for WBC count(11-29 days, 16.4 ± 4.3 days) was similar to ANC, but platelet count and reticulocyte count revealed more delayed data (10-49 days, 19.1 ± 7.4 days vs 17-64 days, 31.4 ± 14.4 days). In conclusion, our results confirm that an increase in the immature reticulocyte population is the earliest sign of the hematopoietic recovery after BMT and that automated reticulocyte quantification including immature fraction may be integrated into clinical protocols to evaluate bone marrow reconstitution.
간경변증 환자에서 Lupus anticoagulant 및 Anti-cardiolipin antibody의 양성율
김홍자(Hing Ja Kim),이성순(Sung Soon Lee),최승목(Sung Mok Choi),김석균(Suk Gyun Kim),정영화(Young Hwa Chung),이영상(Yung Sang Lee),서동진(Dong Jin Suh),서을주(El Ju Suh),지현숙(Hyun Sook Chi) 대한소화기학회 1996 대한소화기학회지 Vol.28 No.5
N/A Background/Aims: Anti-phospholipid antibody syndrome(APS) is clinical syndrome of venous and arterial thrombosis, recurrent fetal losses and thrombo-cytopenia, which are associated with lupus anticoagulant(LA) and/or anti-cardiolipin antibody(aCL). There are some repors about the prevalence of LA and aCL in liver cirrhotics, but enough data are not available in Korean literature, and the menaing of positiveness of t4ese antibodies has been elusive. So, to know the prevalence and clinical meaning of these antibodies in liver cirrhotics in Korea, this study was performed. Methods: Ninety-one patients with liver cirrhosis requiring admission were randomly selected. LA was tested by combination of LA-aPTT, kaolin clotting time and platelet neutrali- zation method, and aCL by ELISA using Imu]yse ACA kit. Clinical data including etiology and severity of liver disease were analysed. Results: Positive rates of LA and aCL were ]6.5% (15/91) and 34.1%(31/91), respectively. 5 out of 91 (5.5%) patients had both anribodies. There were no corre]ations between the positivity of LA and aCL and age,sex, and etiology of liver disease, but the chance to have severe li ier disease (Child class C) was higher in LA positive patients than negative patients(10/15, 66.7% vs 23/76, 30.3%, p=0.001). 5 out of 41 (12.2%) positive cases seemed to have symptoms and signs of possible APS. 4 out of 41(9.8%) had possible primary illnesses other than liver cirrhosis. Conclusions: About one third of cirrhotics requiring admission and treatment had LA and/or aCL, but only few of positive patients were likely to be symptomatic. Severe liver disease(Child class C) could be a risk factor for LA positivity. (Korean J Gastroenterol 1996; 28:669-676)
박수경 ( Soo Kyung Park ),김경조 ( Kyung Jo Kim ),예병덕 ( Byong Duk Ye ),변정식 ( Jeong Sik Byeon ),명승재 ( Seung Jae Myung ),양석균 ( Suk Kyun Yang ),김진호 ( Jin Ho Kim ),지현숙 ( Hyun Sook Chi ) 대한소화기학회 2010 대한소화기학회지 Vol.55 No.1
Although the incidence and prevalence rates of IBD in Korea are still lower than Western populations, they have been increasing rapidly during the past decades. Crohn`s disease (CD) tends to run in families because it is thought to be related to genetic susceptibility coupled with environmental factors. A large number of monozygotic and dizygotic twin pairs with inflammatory bowel disease have been reported in western countries. The population relative risk in first-degree relatives is considered to be about equal in both Koreans and westerners. To our best knowledge, there is no report in monozygotic twins with CD in Korea. This case report is the first documented occurrence of concordant CD occurring in monozygotic twins in Korea. (Korean J Gastroenterol 2010;55:68-72)
지현숙,서을주,강은숙 울산대학교 의과대학 1994 울산의대학술지 Vol.3 No.2
L-carnitine is an essential cofactor for the transport of long-chain fatty acids into mitochondria for β-oxidation. Carnitine deficiencies either due to primary or secondary causes are presented as a myopathic type or systemic type like an encephalopathy due to metabolic disturbances or even fatal cardiomyopathy. The definite diagnosis of carnitine deficiency is based on the determination of free- and acyl-carnitine concentrations in blood, urine, or various tissues and the clinical response to replacement of oral L-carnitine. We reviewed 50 patients requested blood carnitine determination to evaluate diagnostic efficacy of this test. Enzymatic method with carnitine acetyltransferase and acetyl CoA as a substrate was used to determine carnitine concentration in plasma or serum. Normal carnitine levels were obtained from 41 control children and ranged from 7.2 mg/L(44,4 μmol/L) to 12.9 ml/L(79.5 μmol/L). Twenty-four of 50 patients had carnitine concentrations lower than 7.2 mg/L(44.4 μmol/L) and their clinical findings were cardiomyopathy, congenital heart disease complicated with congestive heart failure, organic acidurias and metabolic disturbances. The clinical manifestations of patients were definitely improved in 10 patients out of 16 after treatment with L-carnitine. Early recognition and high dose of carnitine therapy are mainstay of carnitine deficiency. In conclusion, all patients suspected carnitine deficiency either due to primary or secondary causes should be assessed and monitored their carnitine levels before and after treatment.